Fig. 2From: EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanismsNomogram establishment for PCa from TCGA: A nomogram; B 5-year ROC curve; C 5-year calibration curveBack to article page